HK Stock Market Move | XTALPI (02228) rose more than 8% in early trading. The company's business has now extended from AI pharmaceuticals to the AI4S platform.

XTALPI (02228) rose over 8% in early trading, rising 6.98% to HK$10.12 as of the time of writing, with a trading volume of HK$129 million. On the news front, last month, Mirxes, a company specializing in early cancer screening, announced a partnership with AI pharmaceutical platform company Crystal Tai Technology. The two aim to integrate their respective strengths in early detection and drug development to explore an integrated "diagnosis and treatment" solution for high-incidence cancers in Asia. This move is seen as an important attempt to integrate the value chain of cancer prevention and control. Shenwan Hongyuan Group released a research report stating that XTALPI, with its core technology of "physical computing + AI + Siasun Robot & Automation," has established a complete closed loop for early drug development from algorithms and engines to automated laboratories. The company's business has expanded from AI pharmaceuticals to a broader "AI4S" platform, with underlying technology not only accelerating innovation in drug research and development but also showing potential for migration to other fields such as new materials, demonstrating strong technological breadth and platform value. It is given a "buy" rating for the first time.